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Objective To describe suspected adverse drug reactions in cats associated with the 
use of α2-adrenoceptor agonists. 
Study design Retrospective study. 
Animals A total of 90 cats.  
Methods Data were collected from the reports on adverse reactions to veterinary 
medicines sent to the Finnish Medicines Agency during 2003-2013. All reports of 
suspected adverse reactions associated with the use of α2-adrenoceptor agonists in cats 
were included. Probable pulmonary oedema was diagnosed based on post mortem or 
radiological examination, or presence of frothy or excess fluid from the nostrils or 
trachea. If only dyspnoea and crackles on auscultation were reported, possible 
pulmonary oedema was presumed. 
Results Pulmonary oedema was suspected in 61 cases. Of these cats 37 were 
categorised as probable and 24 as possible pulmonary oedema. The first clinical signs 
had been noted between 1 minute and 2 days (median 15 minutes) after the α2-
adrenoceptor agonist administration. Many cats likely had no intravenous 
overhydration when the first clinical signs were detected, as either they presumably 
had no intravenous cannula or the signs appeared before, during or immediately after 
cannulation. Of the 61 cats, 43 survived, 14 died and for 4 the outcome was not 
clearly stated. 
Conclusions and clinical relevance Pulmonary oedema is a perilous condition that 
may appear within minutes of an intramuscular administration of sedative or 
anaesthetic agents in cats. The symptoms were not caused by intravenous 
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overhydration, at least in cats that probably had no venous cannula when the first 





The α2-adrenoceptor agonists are widely used in clinical settings for feline sedation 
and premedication, and in many developed countries xylazine, medetomidine and 
dexmedetomidine have marketing authorisations for this use. These α2-agonists are 
usually administered by intramuscular (IM) route and combined with other drugs such 
as opioids and ketamine (Allen et al. 1986; Verstegen et al. 1989; Selmi et al. 2003; 
Ko et al. 2011). In healthy cats, the use of α2-adrenoceptor agonists alone and 
combined with other sedative and anaesthetic drugs has been considered to be 
efficient and safe (Verstegen et al. 1989; Granholm et al. 2006; McSweeney et al. 
2012). However, the summary of product characteristics (SPC) of the products 
containing medetomidine or dexmedetomidine on the Finnish market states that in 
rare cases pulmonary oedema may occur.  
 
Overall, the risk of anaesthetic- and sedation-related mortality is higher in cats than in 
dogs (Brodbelt et al. 2008, 2010). Poor health status, old age, endotracheal intubation 
and fluid therapy have been associated with the increased risk (Brodbelt et al. 2007). 
Van Der Linde-Sipman et al. (1992) described the necropsy findings of cats that had 
died after injectable anaesthesia, but they did not differentiate the clinical signs or 
post mortem findings associated with separate anaesthetic protocols. Only a single 
report about an adverse reaction associated with the use of α2-adrenoceptor agonists in 
cats in clinical settings can be found in the literature (Raptopoulos et al. 1993). 
 
Before a drug is granted marketing authorisation for European Union (EU) markets, 
its safety is studied by the pharmaceutical company involved and assessed by 
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competent EU authorities. Once the authorisation has been granted, the safety of the 
drug is monitored by the authorities on the basis of adverse reaction reports received 
from veterinarians and users and periodic safety reports from marketing authorisation 
holders. If necessary, changes may be made to the SPC or the package information 
leaflet on the basis of new data. Also the use of the medicine may be restricted or, in 
extreme cases, the marketing authorisation can be cancelled.  
 
The objective of this study was to describe suspected adverse drug reactions in cats 
associated with the use of α2-adrenoceptor agonists in clinical settings. The discussion 
is focused on the signs and potential aetiologies of feline anaesthesia-related 
pulmonary oedema, as it seemed to be the most common adverse reaction reported in 
this material.  
 
Materials and methods 
 
Data were collected from the Finnish Medicines Agency (Fimea) register of adverse 
reactions to veterinary medicinal products. During 2003-2013 Fimea received 2771 
reports of suspected adverse reactions to veterinary medicines of which 464 (16.7%) 
concerned cats. All the 89 reports of suspected adverse reactions associated with the 
use of α2-adrenoceptor agonists in cats (19.2%) were investigated further. One of the 
reports described the reactions of two cats, thus the total number of cats was 90. 
 
We recorded the doses of the drugs and their routes of administration. The onset of 
signs after administration of α2-adrenoceptor agonists was entered if the exact time 
was given in the report. If their onset was only described in relation to the phase of the 
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procedure, we estimated it: during cannulation – 10 minutes; during administration of 
propofol – 15 minutes; at the end of castration – 30 minutes; at the end of 
ovariohysterectomy – 40 minutes; after extubation – 10 minutes after the end of 
surgery. These estimations were partly based on reports where both the exact time and 
the corresponding phase of the procedure were given. Furthermore, we tried to infer 
whether the cat had been intubated and whether it had had an intravenous cannula 
when the first signs were detected. 
 
We judged a probable pulmonary oedema based on clinical signs, i.e. presence of 
frothy or excess fluid from the nostrils or trachea, or on post mortem report or 
radiological diagnosis. We presumed a possible pulmonary oedema when the crackles 
on auscultation were reported to respond to administration of furosemide, or when 
both acute dyspnoea and crackles on auscultation were reported. In addition, we 
recorded a possible pulmonary oedema when the reporting veterinarian had given the 
diagnosis without any pathological or radiological confirmation and without 
describing any clinical signs. 
 
The data were analysed by using IBM SPSS Statistics 22 software. The difference 
between groups for age was analysed with t-test and for onset of clinical signs with 
Mann-Whitney U-test.  The presence of symptoms was compared between dead and 






The 89 reports contained information on 90 cats with suspected adverse reactions 
associated with the use of α2-adrenoceptor agonists. The population consisted of 10 
breeds, most of them being domestic shorthaired cats (n = 53; the breeds of nine cats 
were not specified). Forty-eight cats were female, 37 male and the sex of five cats was 
not given. The age of the cats was 5.1 ± 4.2 years (mean ± SD), ranging from 5 
months to 16 years (for five cats not reported), and their weight was 4.0 ± 1.1 kg (for 
29 cats not reported). The most common indications for sedation or anaesthesia (when 
given) were dental care (n = 21), castration (n = 8) and ovariohysterectomy (n = 7). 
For most of the cats, no preceding diseases were reported, but one of the cats was 
sedated due to urinary tract obstruction, two for enema, one for abscess and one for 
anorexia and vomiting. 
 
Two of the cats had received xylazine as the α2-adrenoceptor agonist, the others had 
been administered medetomidine (n = 58) or dexmedetomidine (n = 30). In most cats 
(n = 80), the IM route was reported to have been used for administration of the α2-
adrenoceptor agonist. One cat was reported to have received the α2-agonist 
intravenously (IV), two subcutaneously and one both IM and IV. In six reports, the 
route of administration was not specified. The recommended doses stated in the SPC 
had been exceeded in none of the cats where the dose of the drugs per body weight 
had been reported or could be calculated. 
 
According to the reports, 37 cats were deduced to have had a probable and 24 cats a 
possible pulmonary oedema. The symptoms of 28 cats were stated to likely not be 
associated with pulmonary oedema (Table 1). In addition, for one cat the presence of 
pulmonary oedema could not be evaluated due to scanty information in the report. All 
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the cats with suspected (probable or possible) pulmonary oedema had received either 
medetomidine or dexmedetomidine as the symptoms of the two cats having been 
administered xylazine (excitation in one cat and vomiting and seizures in the other 
one) were not suggestive to pulmonary oedema. 
 
Two of the 61 cats with suspected pulmonary oedema had evidently received no other 
sedative, anaesthetic or analgesic drug than the α2-adrenoceptor agonist at the time 
when the first signs were noted. The sedative, anaesthetic or analgesic drugs reported 
to have been administered to the cats in addition to the α2-adrenoceptor agonist, and 
evidently before the first signs of the suspected pulmonary oedema, were ketamine (n 
= 19), opioids (butorphanol or buprenorphine; n = 38), propofol (n = 8), midazolam (n 
= 2) and non-steroidal anti-inflammatory drugs (carprofen or meloxicam; n = 5). In 
five reports, the use of other drugs was not clearly stated. In addition, administration 
of antimicrobials (betalactam antibiotics) was mentioned in seven reports. In many 
reports, the exact timing of the administration of the other drugs related to the α2-
adrenoceptor agonist was not specified. 
 
The first clinical signs of pulmonary oedema, such as dyspnoea or frothy sputum, 
were estimated to have appeared between 1 minute and 2 days (median 15 minutes) 
after the administration of the α2-adrenoceptor agonist (Table 1). Only one cat was 
reported to have received IV fluids before the clinical signs of suspected pulmonary 
oedema were detected. That cat was treated for anaesthetic hypotension, after which it 
presented dyspnoea and cyanosis and had pronounced respiratory sounds in 
auscultation; pulmonary oedema was confirmed with chest radiography. Nine other 
cats were deduced to have had an intravenous cannula before onset of the signs of 
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suspected pulmonary oedema, as they had earlier been administered intravenous drugs 
such as propofol. On the other hand, in 28 cats with suspected pulmonary oedema, the 
clinical signs were first noted before, during or immediately after placing the 
intravenous cannula, or there had likely not been enough time to place the cannula 
before onset of signs, as they were perceived within 10 minutes after intramuscular 
administration of the first drugs. The reports of 23 cats did not contain the required 
information to evaluate the presence of an intravenous cannula or the timing of its 
placement and thus their opportunity to have received intravenous fluids before the 
onset of the signs. 
 
The reported interventions after noting the clinical signs of suspected pulmonary 
oedema are presented in Table 2. Most of the cats with suspected pulmonary oedema 
survived (Table 3). The deaths were presumably spontaneous and occurred rather 
soon after the first clinical signs were noted. Nevertheless, one cat died five hours 
after the procedure during which time it had had respiratory problems, and two cats 
were reported to have been euthanized due to poor prognosis; all of these cats were 
categorized as suspected pulmonary oedema. Five of the survived cats had later been 
examined with echocardiography, and no abnormalities were detected. The 
frequencies of some clinical symptoms reported in the cats with suspected pulmonary 
oedema are cross-tabulated with the outcomes in Table 3. 
 
The post mortem findings of ten cats were described in the reports. For six cats, the 
diagnosis of pulmonary oedema was confirmed. For three of these cats, no other 
pathological findings were described, whereas in one anaphylaxis was suspected, 
another one had eosinophilic inflammation in the lungs and the third one had blood in 
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the pericardium, but the heart was reported to have no alterations. The cat with 
suspected anaphylaxis had been sedated with medetomidine and butorphanol, and the 
signs were first noted 10 minutes after the intramuscular injection. One cat reported to 
have had crackles on auscultation and bloody fluid from the lungs, but no specific 
post mortem findings was finally categorised as a possible pulmonary oedema. The 
necropsy findings reported for three other cats did not suggest pulmonary oedema: 
one was diagnosed as acute interstitial pneumonia, one had a chronic subclinical 
pneumonitis and findings suggesting cardiac arrest caused by respiratory arrest and 
one had findings typical of acute cardiac failure. The report of the last cat stated that 




In the reports of adverse reactions to veterinary medicines associated with the use of 
α2-adrenoceptor agonists, approximately two-thirds of the cats had had clinical, 
radiological or autopsy findings suggestive of pulmonary oedema. Only two reports 
mentioned abnormal cardiac necropsy findings. This contradicts the report of Van Der 
Linde-Sipman et al. (1992), who performed autopsies on 36 cats that had died within 
six hours after injectable anaesthesia. They found severe hyperaemia and oedema of 
the lungs and myocardial damage in all of the cats. In most of those cats, no clinical 
signs had been detected before death, but watery fluid from the nostrils, blue mucous 
membranes and dyspnoea were seen in some of them. The authors did not specify 
each cat’s anaesthesia protocol, and therefore, it is not known whether the cats with 
the clinical signs of pulmonary oedema had been administered an α2-adrenoceptor 
agonist (Van Der Linde-Sipman et al. 1992). On the other hand, Gaynor et al. (1999) 
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did not mention pulmonary oedema at all in their report about anaesthesia related 
complications and mortality in cats that were premedicated with a variety of 
sedatives, such as acepromazine, fentanyl, oxymorphone, butorphanol, diazepam, 
tiletamine-zolazepam and xylazine. In our study, most of the cats had been 
administered more than one drug before the onset of clinical signs, and thus, we were 
often unable to confirm whether the α2-adrenoceptor agonist was the specific cause 
for the suspected adverse reaction. 
 
In our study, the clinical signs of the adverse reactions appeared to be detected in 
most cases rather soon after the intramuscular administration of the first drugs, even 
though no exact time was often reported and thus we had to estimate it. The majority 
of the deaths also seemed to have occurred within the first 15-30 minutes. By contrast, 
Brodbelt et al. (2008) describe most of the feline perioperative fatalities to have 
occurred during the postoperative period. This inconsistency may have been caused 
by the different sources of the material, as Brodbelt et al. (2008) collected anaesthesia 
records of all cats anaesthetized and sedated at participating veterinary centres, 
whereas our material consisted of adverse drug reaction reports to the national 
authority on suspected adverse reactions associated with the use of α2-adrenoceptor 
agonist.  
 
In our paper, the most common interventions after detecting an adverse reaction were 
administration of atipamezole, furosemide and oxygen. Oxygen and diuretics are the 
treatments of choice in pulmonary oedema (Clarke et al. 2014). Conversely, although 
atipamezole is widely used for reversing medetomidine and dexmedetomidine 
induced sedation, only few studies describe its cardiovascular effects in cats (Savola 
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1989; Verstegen et al. 1991; Dobromylskyj 1996; Granholm et al. 2006), and no 
reports about its pulmonary effects in this species could be found. Therefore its true 
benefit in cardiopulmonary anaesthetic complications is difficult to evaluate.  
 
In humans, frothy sputum is pathognomonic sign of pulmonary oedema (Chapman et 
al. 2005), and it has also been seen in some horses with perianaesthetic pulmonary 
oedema (Kollias-Baker et al. 1993). In our material, this sign was reported in only 
three of the 25 cats whose diagnosis was confirmed with radiology or necropsy. 
Actually, some of the cats with radiologically confirmed diagnosis of pulmonary 
oedema were reported to have had relatively minor respiratory symptoms. 
Interestingly also, no specific post mortem findings were reported for one cat 
manifesting frothy sputum. Nevertheless, we concluded that the cats with frothy 
sputum and no radiological or post mortem confirmation had a probable pulmonary 
oedema. 
 
In humans, perioperative pulmonary oedema is often associated with fluid overload; 
other precipitating factors are relieving of airway obstruction, neurogenic increase of 
afterload, pulmonary aspiration, anaphylaxis, sepsis, multiple organ failure and 
cardiogenic problems (Chapman et al. 2005). Especially cats with cardiac disease are 
susceptible to pleural effusion or pulmonary oedema induced by overhydration, but 
markedly decreased glomerular filtration rate may also increase the risk (Lunn et al. 
2012). At least in cats that showed the first clinical signs before or immediately after 
they had received a venous cannula, pulmonary oedema was obviously not caused by 




Although myocardial damage has been associated with pulmonary oedema in cats that 
died after injectable anaesthesia (Van Der Linde-Sipman et al. 1992), in our data this 
association was not evident. Cardiac abnormalities had not commonly been detected 
with ultrasonography or in necropsy even when pulmonary oedema had been 
diagnosed with radiographs or necropsy. However, it is possible that undiagnosed 
cardiac diseases existed in some cats, as cardiomyopathy is rather common in 
apparently healthy cats (Paige et al. 2009). Furthermore, we cannot assess the 
reliability of the reported post mortem and radiological findings, as the experience and 
training of the veterinarians performing those studies were not stated. 
 
Pulmonary oedema may occur secondary to upper airway obstruction at least in 
humans (Firdose & Elamin 2004; Chapman et al. 2005), dogs (Kerr 1989) and horses 
(Kollias-Baker et al. 1993). Although not clearly stated in the reports, we expect that 
most of the cats were not intubated, as the clinical signs of pulmonary oedema were 
often detected rather soon after the intramuscular drug injection. Therefore, upper 
airway obstruction cannot be ruled out as a potential cause of the pulmonary oedema 
also in these cats. 
 
Perianaesthetic reflux has been reported in cats (Galatos et al. 2001; Adami et al. 
2011), and it occasionally leads to regurgitation of gastric contents to the mouth 
(Galatos et al. 2001). Furthermore, pulmonary aspiration has been associated with 
pulmonary oedema at least in humans (Chapman et al. 2005). In our material, the 
presence of regurgitation could not be evaluated. Moreover, vomiting was mentioned 
in the reports of a few cats with suspected pulmonary oedema, and thus, aspiration 




Anaphylaxis might have been a possible cause of pulmonary oedema at least in some 
of the cats, and in one cat with pulmonary oedema it was actually suspected based on 
necropsy findings. Clinical manifestations of anaphylactic reactions are species 
dependent, but in the cat, the predominant “shock organ” is the respiratory tract 
(Shmuel & Cortes, 2013). Published reports of anaesthesia-related anaphylactic 
reactions in small animals are rare (Armitage-Chan 2010). In humans, neuromuscular 
blocking agents and antibiotics are common causes of perioperative anaphylaxis 
(Krishna et al. 2014), and especially betalactam antibiotics are often involved in 
severe anaphylaxis (Renaudin et al. 2013). In our material, none of the cats with 
suspected pulmonary oedema were reported to have received neuromuscular blocking 
agents, but some of them had been administered betalactam antibiotics.  
 
The α2-adrenoceptor agonists enhance systemic vascular resistance in cats (Golden et 
al. 1998; Lamont et al 2001; Pypendop et al. 2011), resulting in increases in left 
ventricular preload and afterload (Golden et al. 1998). At least in theory this might 
increase the risk of pulmonary oedema, as a neurogenic increase of afterload is a 
precipitating factor in humans (Chapman et al. 2005). In sheep anaesthetized with 
sevoflurane, massive capillary congestion and alveolar oedema were present within a 
few minutes of dexmedetomidine administration (Kästner et al. 2006). In rats, 
increased permeability of pulmonary endothelium has been proposed to cause 
xylazine-induced pulmonary oedema (Amouzadeh et al 1993), whereas in sheep 
hydrostatic stress has been suggested to be the underlying cause of dexmedetomidine-
induced pulmonary oedema (Kästner et al. 2006). The effects of α2-adrenoceptor 




In our study, approximately one-fifth of the cats with suspected pulmonary oedema 
were reported to have died. However, the mortality rate of cats due to anaesthesia-
related pulmonary oedema cannot be estimated based on these reports, as the sample 
was probably biased; the severity of the symptoms and the outcome of the cat may 
have affected the motivation of the veterinarian to report the case to Fimea. Neither 
can the frequency of feline anaesthesia-related adverse reactions be estimated from 
previous reports on pharmacovigilance (Linnett 2006, Davis et al. 2013, 2015), as it is 
most likely that the adverse reactions are underreported, especially when an adverse 
reaction is expected (e.g. mentioned in the SPC).  
 
In general, marked variation exists in the extent and precision of describing the events 
in the reports of adverse reactions to veterinary medicines. That was especially the 
case in the earlier reports, which were handwritten on a paper form, improving 
somewhat after a uniform electronic form was taken into use in EU in 2005. 
Thereafter veterinarians could copy information directly from their electronic register 
of patients and paste it easily to the electronic form. For the causality assessment it is 
essential that the reports include all details of the medication and a thorough 
description of the event. Thus the importance and necessity of the complete 
information of suspected adverse reactions reports cannot be overemphasized. 
 
In conclusion, pulmonary oedema is a perilous condition that may appear in cats soon 
after administration of α2-adrenoceptor agonists. Its aetiology is not fully understood 
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Table 1 Frequencies of clinical symptoms reported in cats with suspected adverse 
drug reaction associated with the use of α2-adrenoceptor agonists (n = 89), and 
numbers of cats with post mortem and/or radiological examination conducted. In one 
report of a cat that had died, the presence of pulmonary oedema (PE) could not be 
evaluated due to scanty information. 
 
 
 Probable PE 
n = 37 
Possible PE 
n = 24 
Likely not PE 
n = 28 
First clinical signs (minutes) 13 (1 - 2880) 15 (10 – 120) 10 (3 – 2880) 
Excess fluid or frothy sputum (n) 11 1 0 
Crackles on auscultation (n) 18 20 1 
Dyspnoea (n) 16 14 8 
Abdominal breathing pattern (n) 3 2 3 
Apnoea (n) 5 1 7 
Cyanosis (n) 11 3 6 
Other respiratory signs* (n) 5 7 5 
Tachycardia (n) 1 2 2 
Cardiac arrhythmias (n) 7 2 0 
Cardiac arrest (n) 4 0 4 
Opisthotonus/cramp/seizure (n) 16 7 13 
Vomiting (n) 2 1 2 
Prolonged recovery (n) 0 0 2 
Mydriasis (n) 4 2 2 
22 
 
Other clinical signs** (n) 2 4 2 
No clinical signs described (n) 1 2 2 
Thoracic radiography (n) 21 1 1 
Died*** (n) 11 3 6 
Necropsy (n) 6 1 3 
*such as tachypnoea, superficial breathing, wheezing, coughing, hypoxaemia 
**such as too light or too deep sedation, salivation, reddish eyes 
***in five reports, the outcome was not clearly stated; these cats therefore excluded 
when counting the number of cats that had died 
 Results are presented as number of cats (n) or median (range). 
 
Table 2 Reported interventions in 84 cats after detecting clinical signs. In five reports, 
the interventions were not described, and in one report the presence of pulmonary 
oedema (PE) could not be evaluated due to scanty information. These six cats were 
excluded from the table. 
 
 Probable PE 
n = 37 
Possible PE 
n = 22 
Likely not PE 
n = 25 
Intubation (n) 6 1 5 
Oxygen (n) 27 13 7 
Resuscitation (n) 14 2 5 
Furosemide (n) 28 21 11 
Atipamezole (n) 28 20 18 





0 1 1 
Results are presented as number of cats (n). 
 
 
Table 3 Age of the cats, time from drug administration when clinical signs suggestive 
of pulmonary oedema were first noted and frequencies of some clinical symptoms 
reported in cats with suspected pulmonary oedema associated with the use of α2-
adrenoceptor agonists cross-tabulated with outcome. Excluded from the table were 
one dead and two survived cats with no clinical signs reported and four cats whose 




n = 41 
Died 
n = 13 
p 
Age (years) 5.8 ± 5.0 6.0 ± 3.4 0.899 
First clinical signs (minutes) 15 
1 - 300 
10 
5 - 40 
0.213 
Excess fluid or frothy sputum 
(n) 
6 5 0.109 
Crackles on auscultation (n) 31 5 0.020 
Dyspnoea (n) 23 5 0.346 
Abdominal breathing pattern (n) 5 0 0.321 
Apnoea (n) 2 4 0.025 
Cyanosis (n) 11 2 0.485 
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Cardiac arrhythmias (n) 8 0 0.176 
Cardiac arrest (n) 0 4 0.003 
Opisthotonus / cramp / seizure 
(n) 
13 9 0.024 
 
Results are presented as number of cats (n), mean ± standard deviation or median 
(range). 
